These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35747395)

  • 1. Recent insights into the pathogeneses and therapeutic targets of liver diseases: Summary of the 4th Chinese American Liver Society/Society of Chinese Bioscientists in America Hepatology Division Symposium in 2021.
    Ding WX; Wang H; Zhang Y
    Liver Res; 2022 Mar; 6(1):50-57. PubMed ID: 35747395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent insights into the pathogenesis and therapeutic targets of chronic liver diseases.
    Wen Y; Ma L; Ju C
    eGastroenterology; 2023 Oct; 1(2):. PubMed ID: 38074919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage.
    Neuman MG; French SW; Zakhari S; Malnick S; Seitz HK; Cohen LB; Salaspuro M; Voinea-Griffin A; Barasch A; Kirpich IA; Thomes PG; Schrum LW; Donohue TM; Kharbanda KK; Cruz M; Opris M
    Exp Mol Pathol; 2017 Feb; 102(1):162-180. PubMed ID: 28077318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The metabolomic window into hepatobiliary disease.
    Beyoğlu D; Idle JR
    J Hepatol; 2013 Oct; 59(4):842-58. PubMed ID: 23714158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Nutrition in Alcoholic Liver Disease: Summary of the Symposium at the ESBRA 2017 Congress.
    Kharbanda KK; Ronis MJJ; Shearn CT; Petersen DR; Zakhari S; Warner DR; Feldstein AE; McClain CJ; Kirpich IA
    Biomolecules; 2018 Mar; 8(2):. PubMed ID: 29587455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatty Liver Disease and Hepatocellular Carcinoma: The Pathologist's View.
    Tiniakos DG; Maurício J; Reeves HL
    Adv Exp Med Biol; 2018; 1032():55-69. PubMed ID: 30362090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.
    Tokushige K; Ikejima K; Ono M; Eguchi Y; Kamada Y; Itoh Y; Akuta N; Yoneda M; Iwasa M; Yoneda M; Otsuka M; Tamaki N; Kogiso T; Miwa H; Chayama K; Enomoto N; Shimosegawa T; Takehara T; Koike K
    J Gastroenterol; 2021 Nov; 56(11):951-963. PubMed ID: 34533632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut microbiota, fatty liver disease, and hepatocellular carcinoma.
    Chu H; Williams B; Schnabl B
    Liver Res; 2018 Mar; 2(1):43-51. PubMed ID: 30416839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K
    Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights.
    Ikejima K; Kon K; Yamashina S
    Clin Mol Hepatol; 2020 Oct; 26(4):728-735. PubMed ID: 33053942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances.
    Lau JK; Zhang X; Yu J
    J Pathol; 2017 Jan; 241(1):36-44. PubMed ID: 27757953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Key Signaling in Alcohol-Associated Liver Disease: The Role of Bile Acids.
    Way GW; Jackson KG; Muscu SR; Zhou H
    Cells; 2022 Apr; 11(8):. PubMed ID: 35456053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms, biomarkers and targets for therapy in alcohol-associated liver injury: From Genetics to nutrition: Summary of the ISBRA 2018 symposium.
    Kirpich IA; Warner DR; Feng W; Joshi-Barve S; McClain CJ; Seth D; Zhong W; Zhou Z; Osna NA; Kharbanda KK
    Alcohol; 2020 Mar; 83():105-114. PubMed ID: 31129175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review.
    Aghemo A; Alekseeva OP; Angelico F; Bakulin IG; Bakulina NV; Bordin D; Bueverov AO; Drapkina OM; Gillessen A; Kagarmanova EM; Korochanskaya NV; Kucheryavii UA; Lazebnik LB; Livzan MA; Maev IV; Martynov AI; Osipenko MF; Sas EI; Starodubova A; Uspensky YP; Vinnitskaya EV; Yakovenko EP; Yakovlev AA
    Ann Med; 2022 Dec; 54(1):1548-1560. PubMed ID: 35635048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
    Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
    Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.
    Tillman EJ; Rolph T
    Front Endocrinol (Lausanne); 2020; 11():601290. PubMed ID: 33381084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.